In fact, several authors suggest that selectively limiting pro-inflammatory CD4+ T cells to AD brain could enhance the disease prognosis and that repurposing drug strategies directed to regulate pro-inflammatory CD4+ T cells should be considered as plausible therapies for AD [41]. The gene discussed is CD4; the disease is Alzheimer disease.